Safety and Efficacy of Neoadjuvant Radiochemotherapy in Adenocarcinoma of the Gastric-oesophageal Junction

Phase 1/2 Completed 25 enrolled Johannes Gutenberg University Mainz

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the dose limiting toxicity and the maximum tolerable dose of the radiochemotherapy with Docetaxel and Oxaliplatin in patients with adenocarcinoma of the gastric-oesophageal junction.

Timeline

Start: 2005-10
Primary completion: 2013-09
Completion: 2013-09

Publications

Moehler M, Gockel I, Roessler HP, Arnold D, Trarbach T, Thomaidis T, Klautke G, Rodel C, Brenner B, Lang H, Galle PR, Schimanski CC, Schmidberger H. Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction. BMC Cancer. 2013 Feb 11;13:75. doi: 10.1186/1471-2407-13-75.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Docetaxel	Small molecule	20 mg/m2	—
Subject	Docetaxel	Small molecule	25 mg/m2	—
Subject	Oxaliplatin	Small molecule	40 mg/m2	Intravenous
Subject	Oxaliplatin	Small molecule	50 mg/m2	Intravenous

Safety and Efficacy of Neoadjuvant Radiochemotherapy in Adenocarcinoma of the Gastric-oesophageal Junction

Summary

Timeline

Publications

Drugs

Indications